PT  - JOURNAL ARTICLE
AU  - TAKUMI YAMAJI
AU  - KOTARO SHIDE
AU  - TAKURO KAMEDA
AU  - MASAAKI SEKINE
AU  - AYAKO KAMIUNTEN
AU  - TOMONORI HIDAKA
AU  - YOKO KUBUKI
AU  - HARUKO SHIMODA
AU  - HIROO ABE
AU  - TADASHI MIIKE
AU  - HISAYOSHI IWAKIRI
AU  - YOSHIHIRO TAHARA
AU  - MITSUE SUETA
AU  - SHOJIRO YAMAMOTO
AU  - SATORU HASUIKE
AU  - KENJI NAGATA
AU  - KAZUYA SHIMODA
TI  - Loss of Tyrosine Kinase 2 Does Not Affect the Severity of <em>Jak2</em>V617F-induced Murine Myeloproliferative Neoplasm
DP  - 2017 Jul 01
TA  - Anticancer Research
PG  - 3841--3847
VI  - 37
IP  - 7
4099  - http://ar.iiarjournals.org/content/37/7/3841.short
4100  - http://ar.iiarjournals.org/content/37/7/3841.full
SO  - Anticancer Res2017 Jul 01; 37
AB  - Background/Aim: In myeloproliferative neoplasms (MPN), Janus kinase 2 (JAK2) is activated by mutations including JAK2V617F (JAK2VF). It is unclear whether JAK kinases [i.e. JAK1, JAK2, JAK3, or tyrosine kinase 2 (TYK2)] other than JAK2 have cooperative actions such as enhancement or suppression of JAK2. If other kinases enhance activation, therapies that co-target them could have a therapeutic efficacy. We examined the role of TYK2 in Jak2VF-induced murine MPN. Materials and Methods: We crossed Jak2VF transgenic mice and Tyk2-knockout (Tyk2KO) mice to generate Jak2VF/Tyk2KO mice. The disease severity and treatment effect with a JAK2 inhibitor was compared between Jak2VF and Jak2VF/Tyk2KO mice. Results: Both types of mice developed MPN, and there were no differences in peripheral blood counts, spleen weight, or survival period. Upon JAK2 inhibitor therapy, both types of mice had equally improved leukocytosis and splenomegaly. Conclusion: TYK2 does not have cooperative effects with JAK2VF upon MPN onset nor in the presence of a JAK2 inhibitor.